CAR T-cell therapy for ALL uses the target specificity of antibody therapy to direct the cytotoxic immune response4

The autologous anti-CD19 CAR T-cell therapy, TECARTUS, is individually prepared from each patient’s T cells in a 6-step process1:



Obtain peripheral blood mononuclear cells

T cells


Isolate T cells to reduce the likelihood that circulating tumor cells drive the exhaustion of CAR T cells

anti-CD3 and anti-CD28 antibodies + IL-2


Activate T cells using anti-CD3 and anti-CD28 antibodies + IL-2

anti-CD19 CAR transgene


Insert anti-CD19
CAR transgene

CAR T cell expansion
T-cell Expansion

In cell culture, expand the number of CAR T
to achieve dose

CAR T cells in suspension for infusion


Formulate CAR T cells into suspension for infusion

*2-year follow-up analysis was conducted in the 54 efficacy-evaluable patients treated with TECARTUS® in the ZUMA-3 study. Data from the 2-year analysis are not included in the USPI.1,2

ALL=acute lymphoblastic leukemia; CAR=chimeric antigen receptor; CD=cluster of differentiation; IL-2=interleukin-2; R/R=relapsed or refractory; USPI=US Prescribing Information.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. Shah BD, Ghobadi A, Oluwole OO, et al. Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy, in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia in ZUMA-3. Abstract 7010. Poster presented at the American Society of Clinical Oncology Annual Meeting; June 2-6, 2022; Chicago, IL. 3. KYMRIAH®  (tisagenlecleucel). Prescribing information. Novartis Pharmaceuticals Corporation; 2022. 4. Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3-S9.